Successful bought deal offering brings total capital raised to-date to approximately $90 million Increased patent applications filed to 10, covering novel molecules, delivery systems, deuterated
Company Has Raised Nearly CDN$90 Million to Date
– Horizons Psychedelic Stock Index ETF Index now trading on the NEO Exchange –
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Jan. 19, 2021 /CNW/ – Cybin Inc. (NEO: CYBN)
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Jan. 18, 2021 /CNW/ – Cybin Inc. (NEO: CYBN) (“Cybin” or the “Company“), a life sciences
TORONTO, CANADA – January 11, 2021 – Cybin Inc. (NEO:CYBN) (“Cybin”), a life sciences company focused on psychedelic therapeutics, is pleased to announce that Adelia Therapeutics
Cybin is a biotechnology company focused on progressing psychedelics therapeutics.
5600-100 King St W, Toronto,
ON M5X 1C9
© Cybin INC. 2019 All rights reserved.